Vorinostat ( DrugBank: Vorinostat )

3 diseases

19. ライソゾーム病

臨床試験数 : 854 / 薬物数 : 716 - (DrugBank : 105) / 標的遺伝子数 : 70 - 標的パスウェイ数 : 191

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02124083 (ClinicalTrials.gov)	April 25, 2014	25/4/2014	Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1	Phase 1/2 Study of Vorinostat Therapy in Niemann-Pick Disease, Type C1	Neimann-Pick Disease	Drug: Vorinostat	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Washington University School of Medicine;Weill Medical College of Cornell University	Completed	18 Years	60 Years	All	12	Phase 1/Phase 2	United States

臨床試験数 : 203 / 薬物数 : 191 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04339751 (ClinicalTrials.gov)	March 24, 2022	8/4/2020	Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease	The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing's Disease	Cushing's Disease	Drug: Vorinostat	National Institute of Neurological Disorders and Stroke (NINDS)	NULL	Not yet recruiting	18 Years	N/A	All	22	Phase 2	United States

臨床試験数 : 2,400 / 薬物数 : 1,391 - (DrugBank : 267) / 標的遺伝子数 : 170 - 標的パスウェイ数 : 215

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03167437 (ClinicalTrials.gov)	October 30, 2017	24/5/2017	An Open-Label, Proof of Consent Study of Vorinostatfor the Treatment of Mdoerate-to-Severe Crohn s D ...	An Open-Label, Proof of Concept Study of Vorinostatfor the Treatment of Moderate-to-Severe Crohn's D ...	Crohn's Disease	Drug: Vorinostat;Drug: Ustekinumab	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Recruiting	18 Years	65 Years	All	35	Phase 1/Phase 2	United States